Zacks Small Cap Comments on ABEO Q3 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Analysts at Zacks Small Cap issued their Q3 2025 earnings estimates for Abeona Therapeutics in a report released on Monday, March 24th. Zacks Small Cap analyst D. Bautz anticipates that the biopharmaceutical company will earn ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.40 EPS.

Several other equities research analysts have also commented on ABEO. Oppenheimer began coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, March 24th. Finally, StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Stock Down 1.4 %

Abeona Therapeutics stock opened at $4.97 on Thursday. The business’s 50-day moving average price is $5.42 and its 200 day moving average price is $5.81. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $216.05 million, a price-to-earnings ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.19.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in ABEO. Adage Capital Partners GP L.L.C. increased its position in shares of Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Western Standard LLC boosted its stake in Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after purchasing an additional 386,321 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 118,262 shares in the last quarter. 683 Capital Management LLC raised its position in shares of Abeona Therapeutics by 17.3% in the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after buying an additional 116,845 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Abeona Therapeutics in the fourth quarter worth about $520,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.